Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louise Flanagan

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Surgery Open Science|May 3, 2021
A meta-analysis of the use of intraoperative cholangiography; time to revisit our approach to cholecystectomy?Eoin Donnellan, Jonathan Coulter, Cherian Mathew, et al.
Investigative Ophthalmology & Visual Science|February 14, 2016
Glycerol Monolaurate Inhibits Lipase Production by Clinical Ocular Isolates Without Affecting Bacterial Cell ViabilityJudith Louise Flanagan, Neeta Khandekar, Hua Zhu, et al.
The British Journal of Radiology|March 15, 2017
SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspectiveJonathan Wadsley, Rebecca Gregory, Glenn Flux, et al.
BMJ Open|March 25, 2021
MUK<i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemiaSarah Brown, Debbie Sherratt, Samantha Hinsley, et al.
Trials|January 17, 2020
CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trialRob Coleman, Janet Brown, Emma Rathbone, et al.
The Lancet. Haematology|November 16, 2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trialRakesh Popat, Sarah R Brown, Louise Flanagan, et al.
British Journal of Haematology|August 21, 2018
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)Rakesh Popat, Sarah R Brown, Louise Flanagan, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2021
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four TrialSarah Brown, Charlotte Pawlyn, Avie-Lee Tillotson, et al.
BMC Cancer|June 16, 2019
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trialSarah R Brown, Andrew Hall, Hannah L Buckley, et al.
BMC Hematology|May 19, 2016
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Samantha Hinsley, Mónica Ballesteros, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Surgery Open Science|May 3, 2021
A meta-analysis of the use of intraoperative cholangiography; time to revisit our approach to cholecystectomy?Eoin Donnellan, Jonathan Coulter, Cherian Mathew, et al.
Investigative Ophthalmology & Visual Science|February 14, 2016
Glycerol Monolaurate Inhibits Lipase Production by Clinical Ocular Isolates Without Affecting Bacterial Cell ViabilityJudith Louise Flanagan, Neeta Khandekar, Hua Zhu, et al.
The British Journal of Radiology|March 15, 2017
SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspectiveJonathan Wadsley, Rebecca Gregory, Glenn Flux, et al.
BMJ Open|March 25, 2021
MUK<i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemiaSarah Brown, Debbie Sherratt, Samantha Hinsley, et al.
Trials|January 17, 2020
CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trialRob Coleman, Janet Brown, Emma Rathbone, et al.
The Lancet. Haematology|November 16, 2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trialRakesh Popat, Sarah R Brown, Louise Flanagan, et al.
British Journal of Haematology|August 21, 2018
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)Rakesh Popat, Sarah R Brown, Louise Flanagan, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2021
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four TrialSarah Brown, Charlotte Pawlyn, Avie-Lee Tillotson, et al.
BMC Cancer|June 16, 2019
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trialSarah R Brown, Andrew Hall, Hannah L Buckley, et al.
BMC Hematology|May 19, 2016
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Samantha Hinsley, Mónica Ballesteros, et al.
Pageof 3